Короткий опис (реферат):
Malignant peritoneal mesothelioma (MPM) is a rare and aggressive primary peritoneal malignancy. It is characterized by widespread multiple metastatic tumors originating from the mesothelial cells of the peritoneum. Malignant peritoneal mesothelioma (DMPM) accounts for 7-30% of all cases. The incidence of MPM is 800 cases/year in the United States, the prevalence is similar in men and women. The diagnosis is incidental in many patients, detected during abdominal operations in patients with indolent disease and may be co-incidental to other pathology. MPM is divided into 3 main histologic subtypes: epithelioid (50-70%), sarcomatoid (7-20%) and mixed (20-35%) forms. Median survival for the whole group does not exceed 12 months. If surgical treatment is impossible, the overall survival after first-line chemotherapy is about 7 months. In oncological centers cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) allows to achieve a median of survival from 3 to 5 year.
